688319 欧林生物
已收盘 08-25 15:00:01
资讯
新帖
简况
每周股票复盘：欧林生物（688319）Q2净利降396.3%
证券之星 · 08-23
每周股票复盘：欧林生物（688319）Q2净利降396.3%
欧林生物中报遇“税劫”：主业隐忧凸显，高毛利难换高净利
新浪证券 · 08-21
欧林生物中报遇“税劫”：主业隐忧凸显，高毛利难换高净利
8月20日欧林生物涨7.61%，科创创新药ETF国泰基金重仓该股
证券之星 · 08-20
8月20日欧林生物涨7.61%，科创创新药ETF国泰基金重仓该股
欧林生物（688319）2026年中报简析：增收不增利
证券之星 · 08-19
欧林生物（688319）2026年中报简析：增收不增利
欧林生物(688319)6月30日股东户数1.13万户，较上期增加18.88%
证券之星 · 08-18
欧林生物(688319)6月30日股东户数1.13万户，较上期增加18.88%
欧林生物H1转亏正拟发H股 2021上市募4亿英大证券保荐
中金财经 · 08-18
欧林生物H1转亏正拟发H股 2021上市募4亿英大证券保荐
图解欧林生物中报：第二季度单季净利润同比下降396.30%
证券之星 · 08-18
图解欧林生物中报：第二季度单季净利润同比下降396.30%
欧林生物（688319）披露2026年半年度报告，8月17日股价下跌0.56%
证券之星 · 08-17
欧林生物（688319）披露2026年半年度报告，8月17日股价下跌0.56%
股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份质押的公告》
证券之星 · 08-10
股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份质押的公告》
每周股票复盘：泰昌集团再质押400万股欧林生物（688319）股份
证券之星 · 08-09
每周股票复盘：泰昌集团再质押400万股欧林生物（688319）股份
欧林生物（688319）披露持股5%以上股东部分股份质押公告，8月7日股价上涨4.29%
证券之星 · 08-07
欧林生物（688319）披露持股5%以上股东部分股份质押公告，8月7日股价上涨4.29%
欧林生物（688319）股东泰昌集团有限公司质押400万股，占总股本0.99%
证券之星 · 08-07
欧林生物（688319）股东泰昌集团有限公司质押400万股，占总股本0.99%
8月5日欧林生物涨5.24%，科创创新药ETF国泰基金重仓该股
证券之星 · 08-05
8月5日欧林生物涨5.24%，科创创新药ETF国泰基金重仓该股
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”
证券之星 · 08-05
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”
股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告》
证券之星 · 08-05
股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告》
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”
证券之星 · 07-29
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”
7月28日欧林生物跌5.02%，科创创新药ETF国泰基金重仓该股
证券之星 · 07-28
7月28日欧林生物跌5.02%，科创创新药ETF国泰基金重仓该股
每周股票复盘：欧林生物（688319）推进重组金葡菌疫苗海外授权
证券之星 · 07-26
每周股票复盘：欧林生物（688319）推进重组金葡菌疫苗海外授权
欧林生物：公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群
证券日报网 · 07-22
欧林生物：公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群
7月20日欧林生物跌14.37%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-20
7月20日欧林生物跌14.37%，兴全社会价值三年持有混合基金重仓该股
加载更多
公司概况
公司名称：
成都欧林生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-08
主营业务：
成都欧林生物科技股份有限公司的主营业务是创新疫苗的研究、开发、生产及商业化。公司的主要产品是吸附破伤风疫苗、Hib结合疫苗、AC结合疫苗。
发行价格：
9.88
{"stockData":{"symbol":"688319","market":"SH","secType":"STK","nameCN":"欧林生物","latestPrice":28.02,"timestamp":1787641201000,"preClose":27.82,"halted":0,"volume":4691740,"delay":0,"changeRate":0.0072,"floatShares":405000000,"shares":405000000,"eps":-0.0588,"marketStatus":"已收盘","change":0.2,"latestTime":"08-25 15:00:01","open":27.58,"high":28.45,"low":27.04,"amount":130000000,"amplitude":0.0507,"askPrice":28.08,"askSize":20,"bidPrice":28.02,"bidSize":39,"shortable":0,"etf":0,"ttmEps":-0.0588,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":5,"adr":0,"adjPreClose":27.82,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787621400000,1787628600000],[1787634000000,1787641200000]],"highLimit":30.6,"lowLimit":25.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":405409300,"isCdr":false,"pbRate":13.07,"roa":"--","roe":"--","epsLYR":0.0549,"committee":0.113553,"marketValue":11360000000,"turnoverRate":0.0116,"status":0,"afterMarket":{"amount":0,"volume":0,"close":28.02,"buyVolume":1900,"sellVolume":0,"time":1787643237746,"indexStatus":"已收盘 08-25 15:30:00","preClose":27.82},"floatMarketCap":11360000000},"requestUrl":"/m/hq/s/688319","defaultTab":"news","newsList":[{"id":"2661321178","title":"每周股票复盘：欧林生物（688319）Q2净利降396.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661321178","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661321178?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:37","pubTimestamp":1787423828,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，欧林生物报收于30.05元，较上周的28.54元上涨5.29%。本周，欧林生物8月21日盘中最高价报31.12元。本周关注点股本股东变化：截至2026年6月30日股东户数增至1.13万户，增幅18.88%。业绩披露要点：2026年第二季度归母净利润-6006.19万元，同比下降396.3%。3个上市疫苗检定合格率和批签发获证率均为100%，通过多项GMP检查。重组金葡菌疫苗III期临床数据揭盲完成，保护效力达73.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661257723","title":"欧林生物中报遇“税劫”：主业隐忧凸显，高毛利难换高净利","url":"https://stock-news.laohu8.com/highlight/detail?id=2661257723","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661257723?lang=zh_cn&edition=full","pubTime":"2026-08-21 14:45","pubTimestamp":1787294700,"startTime":"0","endTime":"0","summary":"近日，欧林生物披露2026年半年报。01一次性税务事项制造巨亏，利润扰动口径需厘清本次欧林生物上半年利润大幅转亏，核心导火索是历史税务相关事项，合计对利润表造成约8320万元冲击。欧林生物三款商业化疫苗中，吸附破伤风疫苗是绝对支柱，2025年该产品收入占主营业务收入87.65%，市场收入份额高达98.8%，单品依赖度极高。单品高度集中、销售费用高企，已经成为欧林生物绕不开的矛盾。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-08-21/doc-inipaenp6467103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660120402","title":"8月20日欧林生物涨7.61%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660120402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660120402?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:37","pubTimestamp":1787215063,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日欧林生物涨7.61%，收盘报29.4元，换手率3.76%，成交量15.25万手，成交额4.54亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9451，较上一交易日下跌3.03%，近一年下跌8.54%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319","589720"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660497031","title":"欧林生物（688319）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660497031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660497031?lang=zh_cn&edition=full","pubTime":"2026-08-19 06:05","pubTimestamp":1787090744,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期欧林生物发布2026年中报。根据财报显示，欧林生物增收不增利。截至本报告期末，公司营业总收入3.61亿元，同比上升18.14%，归母净利润-3287.26万元，同比下降349.09%。一年内到期的非流动负债变动幅度为110.65%,原因:一年内到期的长期借款增加。持有欧林生物最多的基金为科创创新药ETF国泰，目前规模为21.97亿元，最新净值0.9746，较上一交易日下跌0.52%，近一年下跌7.15%。本文数据来源于欧林生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900003991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465161","title":"欧林生物(688319)6月30日股东户数1.13万户，较上期增加18.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465161","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660465161?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:27","pubTimestamp":1787045256,"startTime":"0","endTime":"0","summary":"证券之星消息，近日欧林生物披露，截至2026年6月30日公司股东户数为1.13万户，较3月31日增加1798.0户，增幅为18.88%。在生物制品行业个股中，欧林生物股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.53万户。从股价来看，2026年3月31日至2026年6月30日，欧林生物区间涨幅为51.34%，在此期间股东户数增加1798.0户，增幅为18.88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459884","title":"欧林生物H1转亏正拟发H股 2021上市募4亿英大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459884","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459884?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:03","pubTimestamp":1787022185,"startTime":"0","endTime":"0","summary":"中国经济网北京8月18日讯 欧林生物 昨晚披露的2026年半年度报告显示，公司上半年营业收入3.61亿元，同比增长18.14%；归属于上市公司股东的净利润-0.33亿元，上年同期为0.13亿元；归属于上市公司股东的扣除非经常性损益的净利润-0.10亿元，上年同期为0.08亿元；经营活动产生的现金流量净额-0.70亿元，上年同期为-0.20亿元。 欧林生物首次公开发行股票的发行费用为4159.91万元，其中保荐及承销费3013.05万元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/18/20260818306285.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/18/20260818306285.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260818/32338084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688319","IPOS","BK0239","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431323","title":"图解欧林生物中报：第二季度单季净利润同比下降396.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431323","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431323?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:26","pubTimestamp":1786987593,"startTime":"0","endTime":"0","summary":"证券之星消息，欧林生物2026年中报显示，上半年度公司主营收入3.61亿元，同比上升18.14%；归母净利润-3287.26万元，同比下降349.09%；扣非净利润-1006.2万元，同比下降230.28%；其中2026年第二季度，公司单季度主营收入2.04亿元，同比下降6.8%；单季度归母净利润-6006.19万元，同比下降396.3%；单季度扣非净利润-3334.01万元，同比下降277.85%；负债率58.6%，投资收益12.51万元，财务费用851.45万元，毛利率91.81%。财报数据概要请见下图:本文数据来源于欧林生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435852","title":"欧林生物（688319）披露2026年半年度报告，8月17日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435852","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660435852?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:17","pubTimestamp":1786976261,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，欧林生物报收于28.38元，较前一交易日下跌0.56%，最新总市值为115.06亿元。该股当日开盘28.62元，最高29.27元，最低28.01元，成交额达1.95亿元，换手率为1.7%。近日，成都欧林生物科技股份有限公司披露2026年半年度报告。公告显示，公司总资产为2,099,715,731.97元，较上年度末增长3.79%；归属于上市公司股东的净资产为869,325,887.95元，较上年度末减少3.80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670271","title":"股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670271?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:40","pubTimestamp":1786297222,"startTime":"0","endTime":"0","summary":"公司公告汇总成都欧林生物科技股份有限公司关于持股5%以上股东部分股份质押的公告股东泰昌集团有限公司持有公司股份25,893,040股，占公司总股本的6.39%；本次质押4,000,000股，占其持股总数的15.45%，占公司总股本的0.99%；质押起始日为2026年8月3日，质权人为杭州银行温州科技支行，用途为融资担保；本次质押后，泰昌集团累计质押股份19,410,000股，占其持股总数的74.96%，占公司总股本的4.79%；已质押及未质押股份均无限售、冻结或其他权利限制情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658067370","title":"每周股票复盘：泰昌集团再质押400万股欧林生物（688319）股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2658067370","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658067370?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:11","pubTimestamp":1786212670,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，欧林生物报收于27.23元，较上周的21.56元上涨26.3%。本周，欧林生物8月7日盘中最高价报27.28元。公司于2026年8月4日收到泰昌集团关于部分股份解除质押的通知函，相关手续已办理完毕。成都欧林生物科技股份有限公司股东泰昌集团有限公司持有公司股份25,893,040股，占公司总股本的6.39%。本次质押后，泰昌集团累计质押公司股份19,410,000股，占其持股总数的74.96%，占公司总股本的4.79%。已质押股份无限售股、冻结股，未质押股份也无限制情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644621","title":"欧林生物（688319）披露持股5%以上股东部分股份质押公告，8月7日股价上涨4.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644621","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644621?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:20","pubTimestamp":1786112411,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，欧林生物报收于27.23元，较前一交易日上涨4.29%，最新总市值为110.39亿元。该股当日开盘26.14元，最高27.28元，最低25.68元，成交额达2.85亿元，换手率为2.64%。公告显示，公司股东泰昌集团有限公司持有公司股份25,893,040股，占公司总股本的6.39%。本次质押4,000,000股，占其持股总数的15.45%，占公司总股本的0.99%。质押起始日为2026年8月3日，质押给杭州银行温州科技支行，用于融资担保。已质押股份无限售股、冻结股，未质押股份也无限制情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612285","title":"欧林生物（688319）股东泰昌集团有限公司质押400万股，占总股本0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657612285?lang=zh_cn&edition=full","pubTime":"2026-08-07 18:24","pubTimestamp":1786098271,"startTime":"0","endTime":"0","summary":"证券之星消息，欧林生物8月7日公开信息显示，股东泰昌集团有限公司向杭州银行温州科技支行合计质押400.0万股，占总股本0.99%。质押详情见下表：截止本公告日，股东泰昌集团有限公司已累计质押股份1941.0万股，占其持股总数的74.96%。欧林生物主营业务：人用疫苗产品研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700033673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657514990","title":"8月5日欧林生物涨5.24%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657514990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657514990?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:40","pubTimestamp":1785919221,"startTime":"0","endTime":"0","summary":"证券之星消息，8月5日欧林生物涨5.24%，收盘报24.5元，换手率2.17%，成交量8.78万手，成交额2.13亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.8542，较上一交易日上涨3.26%，近一年下跌13.54%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500030193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","589720","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657566165","title":"欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657566165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657566165?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:48","pubTimestamp":1785872938,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示欧林生物新获得一项发明专利授权，专利名为“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”，专利申请号为CN202411986210.2，授权日为2026年8月4日。本发明提供的一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用，解决了现有技术检测二油酰基磷脂酰胆碱和胆固醇含量，以及皂树皂苷QS21含量需要两种不同方法进行两次检测的技术问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500005135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756312","title":"股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657756312?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:59","pubTimestamp":1785866349,"startTime":"0","endTime":"0","summary":"公司公告汇总成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告成都欧林生物科技股份有限公司股东泰昌集团有限公司持有公司股份25,893,040股，占公司总股本的6.39%。本次解除质押股份数量为4,000,000股，解除质押后累计质押股份15,410,000股，占其持股总数的59.51%，占公司总股本的3.80%。公司于2026年8月4日收到泰昌集团关于部分股份解除质押的通知函，相关手续已办理完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882485","title":"欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655882485?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:32","pubTimestamp":1785267164,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示欧林生物新获得一项发明专利授权，专利名为“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”，专利申请号为CN202510731018.7，授权日为2026年7月28日。本发明提供的一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂、类脂含量的方法及应用，解决了现有技术检测复合佐剂中皂苷类免疫增强剂和类脂含量需要至少两种不同方法进行至少两次检测的技术问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900003187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077596","title":"7月28日欧林生物跌5.02%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077596","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654077596?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:44","pubTimestamp":1785228267,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日欧林生物跌5.02%创60日新低，收盘报23.25元，换手率3.27%，成交量13.26万手，成交额3.19亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9225，较上一交易日上涨2.56%，近一年下跌7.53%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319","589720"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654522750","title":"每周股票复盘：欧林生物（688319）推进重组金葡菌疫苗海外授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654522750","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654522750?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:51","pubTimestamp":1785001874,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，欧林生物报收于25.63元，较上周的30.41元下跌15.72%。来自机构调研要点：重组金葡菌疫苗第二适应症拟用于压疮预防，预计今年申报临床批件。公司重组金葡菌疫苗则提供了一种预防的手段，对于患者家庭而言，也是减少成员疾病发生、减少医疗费用的有效手段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653696707","title":"欧林生物：公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2653696707","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653696707?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:53","pubTimestamp":1784728380,"startTime":"0","endTime":"0","summary":"证券日报网7月22日讯，欧林生物在接受调研时表示，公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群。选择骨科手术为适应症，一方面是因为骨科手术中金葡菌感染率较高，另一方面是因为骨科手术患者相比之下自身免疫情况较好，有助于临床试验的成功。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-22/doc-iniisxzt1865167.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-22/doc-iniisxzt1865167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BMED","IBBJ","MDTX","PSYK","159646","IBBQ","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652296803","title":"7月20日欧林生物跌14.37%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652296803","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652296803?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:29","pubTimestamp":1784536148,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日欧林生物跌14.37%创60日新低，收盘报26.04元，换手率4.44%，成交量17.99万手，成交额4.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787701317079,"stockEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":0.0933},{"period":"3month","weight":-0.2653},{"period":"6month","weight":0.0193},{"period":"1year","weight":-0.1423},{"period":"ytd","weight":0.1049}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都欧林生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11320人(较上一季度增加18.88%)","perCapita":"35813股","listingDate":"2021-06-08","address":"四川省成都市郫都区高新区天欣路99号","registeredCapital":"40540万元","survey":" 成都欧林生物科技股份有限公司的主营业务是创新疫苗的研究、开发、生产及商业化。公司的主要产品是吸附破伤风疫苗、Hib结合疫苗、AC结合疫苗。","listedPrice":9.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧林生物,688319,欧林生物股票,欧林生物股票老虎,欧林生物股票老虎国际,欧林生物行情,欧林生物股票行情,欧林生物股价,欧林生物股市,欧林生物股票价格,欧林生物股票交易,欧林生物股票购买,欧林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}